Clinical Significance of Detecting Plasma Biomarkers of Prethrombotic State in Lung Cancer Patients_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

ChengKebin , GaoBeilan , LiuJinming , SuYiliang ,  XuJinfu

Department of Respiratory Medicine, Shanghai Pulmonary Hospital Affiliated to Tongji University of Medical school, Shanghai, 200433, China;

Corresponding author：

XuJinfu, Email: jfxucn@gmail.com

Keywords：

Lung cancer; Prothrombotic state; Biomarkers

DOI：

10.7507/1671-6205.2014093

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the clinical significance of plasma biomarkers of prethrombotic state in lung cancer patients. Methods 90 patients with lung cancer (lung cancer group) and 90 normal controls (control group) of Han population in Shanghai Pulmonary Hospital from June 2010 to June 2012 were recruited in the study. Enzyme-linked immunosorbent assay (ELISA) was used to detect the plasma levels of von willebrand factor(vWF),P-selectin,and thrombin-antithrombine complex (TAT). Coagulation indicators were detected by ACLTOP full automatic coagulation analyzer. Solidification method was used to detect the plasma levels of prothrombin time (PT),activated partial thromboplastin time (APTT) and fibrinogen (FIB). Turbidimetric immunoassay was used to detect D-dimer concentration,and chemiluminescence substrate was used to assay antithrombin Ⅲ (AT-Ⅲ). Results In the lung cancer group,the plasma levels of vWF,P-selectin,TAT,D-dimer and FIB were significantly higher than those in the control group (P<0.05),and the plasma levels of APTT and AT-Ⅲ were lower than those in the control group(P<0.05),while there was no significant difference in plasma PT level(P>0.05). In stage Ⅳ lung cancer subgroup,the plasma levels of vWF,P-selectin,TAT,D-dimer and FIB were significantly higher than those in the stage Ⅲ subgroup or the stage Ⅰ+Ⅱ subgroup (P<0.05). And the plasma levels of PT and APTT were significantly lower than those in the stage Ⅲ subgroup or the stage Ⅰ+Ⅱ subgroup (P<0.05). Conclusion The patients with lung cancer exist obvious prethrombotic state. AT-Ⅲ,vWF, D-dimer, FIB,TAT,P-selectin and APTT can be used as reliable hematol markers in early diagnosis of prethrombotic state. vWF,P-selectin,TAT and D-dimer have higher sensitivity and specificity.

Citation： ChengKebin, GaoBeilan, LiuJinming, SuYiliang, XuJinfu. Clinical Significance of Detecting Plasma Biomarkers of Prethrombotic State in Lung Cancer Patients. Chinese Journal of Respiratory and Critical Care Medicine, 2014, 13(4): 381-384. doi: 10.7507/1671-6205.2014093 Copy

1.	Falanga A,Tickles FR.Pathophysiology of the thrombophilic state in the cancer patient.Semin Thromb Hemost,1999,25:173-182.
2.	Chew HK,Davies AM,Wun T,et al.The incidence of venous thromboembolism among patients with primary lung cancer.Thromb Haemost,2008,6:601-608.
3.	Lee JE,Kim HR,Lee SM,et al.Clinical characteristies of pulmonary embolism with underlying maligrtancy.Korean J Int Med,2010,25:66-70.
4.	向琪,刘敏娟.肺癌和卵巢癌患者相关标志物的实验研究.血栓与止血学,2010,16:27-28.
5.	Tsai AW,Cushman M,Rosamond WD,et al.Coagulation factors,inflammation markers,and venous thromboembolism:the longitudinal investigation of thromboembolism etiology (LITE).Am J Med,2002,113:636-642.
6.	Terraube V,Marx I,Denis CV.Role of von Willebrand factor in tumor metastasis.Thromb Res,2007,120 Suppl 2:S64-S70.
7.	Merten M,Thiagarajan P.P-seleetin in arterial thrombosis.Z Kardiol,2004,93:855-863.
8.	Tseng JC,Chang LC,Jiang BY,et al.Elevated circulating levels of tissue factor-positive microvesicles are associated with distant metastasis in lung cancer.J Cancer Res Clin Oncol,2014,140:61-67.
9.	Ay C,Simanek R,Vormittag R,et al.High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients:results from the Vienna Cancer and Thrombosis Study (CATS). Blood,2008,112:2703-2738.
10.	McCarty OJ,Mousa SA,Bray PF,et al.Immobilized platelets support human colon carcinoma cell tethering,roling,and firm adhesion under dynamic flow conditions.Blood,2000,96:1789-1797.
11.	Connolly GC,Francis CW.Cancer-associated thrombosis. Hematology Am Soc Hematol Educ Program,2013,2013:684-691.
12.	叶跃红,李兴禄.血栓前状态实验室诊断指标研究.重庆医学,2005,34:366-367.
13.	魏让,郭爱芝.不同肿瘤患者血浆纤维蛋白原水平的相关性研究.山西医药杂志,2005,34:100-101.
14.	Ay C,Vormittag R,Dunkler D,et al.D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer:results from the Vienna Cancer and Thrombosis Study.J Clin Oncol,2009,27:4124-4129.
15.	Ay C,Dunkler D,Pirker R,et al.High D-dimer levels are associated with poor prognosis in cancer patients.Haematologica,2012,97:1158-1164.
16.	Sorensen HT,Mellemkjaer L,Olsen JH,et al.Prognosis of cancers associated with venous thromboembolism.N Engl J Med,2000,343:1846-1850.
17.	Kuderer NM,Khorana AA,Lyman GH,et al.A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment:Impact on survival and bleeding complications.Cancer,2007,110:1149-1161.
18.	Corrales-Rodriguez L,Blais N.Lung cancer associated venous thromboembolic disease:a comprehensive review.Lung Cancer,2012,75:1-8.
19.	Lyman GH,KhoranaAA,Falanga A,et al.American Society of Clinical Oncology Guideline:Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer.J Clin Oncol,2007,25:5490-5505.
20.	Wun T,White RH.Epidemiology of cancer-related venous thromboembolism.Best Pract Res Clin Haematol,2009,22:9-23.

1. Falanga A,Tickles FR.Pathophysiology of the thrombophilic state in the cancer patient.Semin Thromb Hemost,1999,25:173-182.
2. Chew HK,Davies AM,Wun T,et al.The incidence of venous thromboembolism among patients with primary lung cancer.Thromb Haemost,2008,6:601-608.
3. Lee JE,Kim HR,Lee SM,et al.Clinical characteristies of pulmonary embolism with underlying maligrtancy.Korean J Int Med,2010,25:66-70.
4. 向琪,刘敏娟.肺癌和卵巢癌患者相关标志物的实验研究.血栓与止血学,2010,16:27-28.
5. Tsai AW,Cushman M,Rosamond WD,et al.Coagulation factors,inflammation markers,and venous thromboembolism:the longitudinal investigation of thromboembolism etiology (LITE).Am J Med,2002,113:636-642.
6. Terraube V,Marx I,Denis CV.Role of von Willebrand factor in tumor metastasis.Thromb Res,2007,120 Suppl 2:S64-S70.
7. Merten M,Thiagarajan P.P-seleetin in arterial thrombosis.Z Kardiol,2004,93:855-863.
8. Tseng JC,Chang LC,Jiang BY,et al.Elevated circulating levels of tissue factor-positive microvesicles are associated with distant metastasis in lung cancer.J Cancer Res Clin Oncol,2014,140:61-67.
9. Ay C,Simanek R,Vormittag R,et al.High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients:results from the Vienna Cancer and Thrombosis Study (CATS). Blood,2008,112:2703-2738.
10. McCarty OJ,Mousa SA,Bray PF,et al.Immobilized platelets support human colon carcinoma cell tethering,roling,and firm adhesion under dynamic flow conditions.Blood,2000,96:1789-1797.
11. Connolly GC,Francis CW.Cancer-associated thrombosis. Hematology Am Soc Hematol Educ Program,2013,2013:684-691.
12. 叶跃红,李兴禄.血栓前状态实验室诊断指标研究.重庆医学,2005,34:366-367.
13. 魏让,郭爱芝.不同肿瘤患者血浆纤维蛋白原水平的相关性研究.山西医药杂志,2005,34:100-101.
14. Ay C,Vormittag R,Dunkler D,et al.D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer:results from the Vienna Cancer and Thrombosis Study.J Clin Oncol,2009,27:4124-4129.
15. Ay C,Dunkler D,Pirker R,et al.High D-dimer levels are associated with poor prognosis in cancer patients.Haematologica,2012,97:1158-1164.
16. Sorensen HT,Mellemkjaer L,Olsen JH,et al.Prognosis of cancers associated with venous thromboembolism.N Engl J Med,2000,343:1846-1850.
17. Kuderer NM,Khorana AA,Lyman GH,et al.A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment:Impact on survival and bleeding complications.Cancer,2007,110:1149-1161.
18. Corrales-Rodriguez L,Blais N.Lung cancer associated venous thromboembolic disease:a comprehensive review.Lung Cancer,2012,75:1-8.
19. Lyman GH,KhoranaAA,Falanga A,et al.American Society of Clinical Oncology Guideline:Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer.J Clin Oncol,2007,25:5490-5505.
20. Wun T,White RH.Epidemiology of cancer-related venous thromboembolism.Best Pract Res Clin Haematol,2009,22:9-23.

Chinese Journal of Respiratory and Critical Care Medicine

Clinical Significance of Detecting Plasma Biomarkers of Prethrombotic State in Lung Cancer Patients

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content